MinorityHeartHealth.org
  • Home
  • About Us
  • Issues
    • Quality Measures
    • Veterans
    • 1,000,000 Hearts Initiative
    • Hospital Adherence
  • Facts and FIndings
    • The Data
    • The Evidence
    • Patient Access Study
    • NQF Quality Measure
  • Blog
  • Get Involved
    • Voices for Change
    • Join Us

Patient Access

Out-of-Pocket Payment Issues

Some stakeholders have expressed ambivalence, or even opposition, to quality measures encouraging the used of the fixed-dose combination of hydralazine hydrochloride and isosorbide dinitrate (BiDil) due to the concern that African Americans seeking treatment for heart failure cannot afford it. A recent study by the National Minority Quality Forum has found, however, that in 2013 the median out-of-pocket payment per tablet by African American Medicare beneficiaries for whom the therapy was indicated was only $0.06, and that 25% of beneficiaries had no out-of-pocket expenditure for the medication.

A comprehensive issue brief on these findings is available below.
Powered by Create your own unique website with customizable templates.
  • Home
  • About Us
  • Issues
    • Quality Measures
    • Veterans
    • 1,000,000 Hearts Initiative
    • Hospital Adherence
  • Facts and FIndings
    • The Data
    • The Evidence
    • Patient Access Study
    • NQF Quality Measure
  • Blog
  • Get Involved
    • Voices for Change
    • Join Us